291
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Intrathecal Drug Delivery Systems Survey: Trends in Utilization in Pain Practice

, , , , , ORCID Icon, , , ORCID Icon & show all
Pages 1305-1314 | Published online: 03 May 2022

References

  • Duarte RV, Lambe T, Raphael JH, Eldabe S, Andronis L. Intrathecal drug delivery systems for the management of chronic noncancer pain: a systematic review of economic evaluations. Pain Pract. 2018;18(5):666–686. doi:10.1111/papr.12650
  • Stearns LJ, Narang S, Albright RE, et al. Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw open. 2019;2(4):e191549. doi:10.1001/jamanetworkopen.2019.1549
  • Wallace M, Yaksh TL. Long-term spinal analgesic delivery: a review of the preclinical and clinical literature. Reg Anesth Pain Med. 2000;25(2):117–157.
  • Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation. 2017;20(2):155–176. doi:10.1111/ner.12579
  • Deer TR, Pope JE, Hanes MC, McDowell GC. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options. Pain Med. 2019;20(4):784–798. doi:10.1093/pm/pny132
  • Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20(2):96–132.
  • Accreditation Council for Graduate Medical Education. Data resource book: academic year 2018–2019; 2019.
  • AAMC. Active physicians by sex and speciality. physician specialty data report; 2019. Available from: https://www.aamc.org/data-reports/workforce/interactive-data/active-physicians-sex-and-specialty-2019. Accessed April 16, 2022.
  • AAMC. 2020 physician specialty report data highlights. physician specialty data report; 2020. Available from: https://www.aamc.org/data-reports/workforce/interactive-data/2020-physician-specialty-report-data-highlights. Accessed April 16, 2022.
  • Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17(4):354–72; discussion 372. doi:10.1111/ner.12146
  • An Updated Report by the American Society of Anesthesiologists Task Force on Neuraxial Opioids. Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration: an updated report by the American Society of Anesthesiologists Task Force on Neuraxial Opioids and the American So. Anesthesiology. 2016;124(3):535–552. doi:10.1097/ALN.0000000000000975
  • Abd-Elsayed A, Karri J, Michael A, et al. Intrathecal drug delivery for chronic pain syndromes: a review of considerations in practice management. Pain Physician. 2020;23(6):E591–617.
  • Carvalho B. Respiratory depression after neuraxial opioids in the obstetric setting. Anesth Analg. 2008;107(3):956–961. doi:10.1213/ane.0b013e318168b443
  • Shapiro A, Zohar E, Zaslansky R, Hoppenstein D, Shabat S, Fredman B. The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth. 2005;17(7):537–542. doi:10.1016/j.jclinane.2005.01.006
  • Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10(2):357–366. doi:10.36076/ppj.2007/10/357
  • Belzarena SD. Clinical effects of intrathecally administered fentanyl in patients undergoing cesarean section. Anesth Analg. 1992;74(5):653–657.
  • Cornish PB. Respiratory arrest after spinal anesthesia with lidocaine and fentanyl. Anesth Analg. 1997;84(6):1387–1388. doi:10.1213/00000539-199706000-00041
  • Rosenberger LH, Politano AD, Sawyer RG. The surgical care improvement project and prevention of post-operative infection, including surgical site infection. Surg Infect. 2011;12(3):163–168. doi:10.1089/sur.2010.083
  • Engle MP, Vinh BP, Harun N, Koyyalagunta D. Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center. Pain Physician. 2013;16(3):251–257.
  • Scanlon MM, Gazelka HM, Moeschler SM, et al. Surgical site infections in cancer patients with intrathecal drug delivery devices. Pain Med. 2017;18(3):520–525.
  • Malheiro L, Gomes A, Barbosa P, Santos L, Sarmento A. Infectious complications of intrathecal drug administration systems for spasticity and chronic pain: 145 patients from a tertiary care center. Neuromodulation. 2015;18(5):421–427. doi:10.1111/ner.12265
  • Sindt JE, Larsen SD, Dalley AP, Collier WH, Brogan SE. The rate of infectious complications after intrathecal drug delivery system implant for cancer-related pain is low despite frequent concurrent anticancer treatment or leukopenia. Anesth Analg. 2020;131(1):280–287. doi:10.1213/ANE.0000000000004639
  • Hoelzer BC, Bendel MA, Deer TR, et al. Spinal cord stimulator implant infection rates and risk factors: a multicenter retrospective study. Neuromodulation. 2017;20(6):558–562. doi:10.1111/ner.12609
  • Kamran S, Wright BD. Complications of intrathecal drug delivery systems. Neuromodulation. 2001;4(3):111–115. doi:10.1046/j.1525-1403.2001.00111.x
  • Adler JA, Lotz NM. Intrathecal pain management: a team-based approach. J Pain Res. 2017;10:2565–2575. doi:10.2147/JPR.S142147